ASGCT 2024: Cell Therapy Post-Conference Report

Join us as we explore the advancements presented at the 2024 ASGCT Annual Meeting. Our analyst team has screened the abstracts presented and identified 114 abstracts (30 clinical, 4 trial outline, 78 preclinical, and 2 both clinical and preclinical) associated with trial or drug records on Beacon Cell Therapy, providing insights and comprehensive coverage through our exclusive planner and report. Download today and stay informed about the latest developments in the space.

ASGCT 2024: Cell Therapy Abstract Highlights

This report provides a comprehensive guide to cell therapy abstracts presented at the conference. It includes an analysis of these abstracts, focusing on the distribution of therapeutic class, disease indication and target. Additionally, it provides a summary breakdown that includes:

  • Trial Sponsors: Overview of key sponsors behind the trials.
  • Clinical Phases: Summary of the clinical phases represented, from early-stage to advanced research.
  • Disease Indications and Results: Comprehensive look at disease indications covered and trial outcomes.
  • Safety Outcomes: Analysis of safety data for these therapies.

We hope you find this report valuable and insightful and are as excited as we are to see the latest developments in cell therapy.

You May Also Be Interested In…

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more

Menu
Search Icon
Close Icon
Search